Gabapentin and Pressor Response to Intubation
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-59
SponsorLiaquat National Hospital & Medical College
About this trial
This study evaluates the effectiveness of oral gabapentin in reducing the pressor response (increased MAP, HR, and BP) during laryngoscopic intubation. It is a prospective, double-blind randomized controlled trial involving 144 patients undergoing elective surgery. Gabapentin 300 mg or placebo will be administered preoperatively, with hemodynamic parameters monitored before and after intubation. The study aims to determine if gabapentin attenuates the sympathetic stress response compared to placebo.
Eligibility criteria
Qualifiers
ASA I or II patients (American Society of Anesthesiologists Physical Status Classification).
Age between 18 and 59 years.
Scheduled for elective surgery under general anesthesia with endotracheal intubation.
Disqualifiers
Anticipated difficult intubation.
ASA III or greater.
Patients with hiatus hernia or gastro-esophageal reflux disease (GERD).
Body weight more than 20% of ideal body weight.
Trial design
Treatments tested in this trial
- Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin
- Placebo Oral Tablet
Treatment groups
144 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov